NETRIS Pharma is a spin-off of Centre Léon Bérard and the Cancer Research Center of Lyon (CRCL) in Lyon, France. The company focuses on therapeutic innovation in cancer care, benefiting from the environment of a comprehensive center dedicated to cancer care, education, and research.

NETRIS Pharma

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes bi-hormonal products, which include BioChaperone AsPram, which is a combination of rapid insulin aspart with pramlintide; and BioChaperone Glargine Liraglutidea, which is a fixed combination of insulin glargine with an analogue of the GLP-1 receptor. In addition, the company's preclinical pipeline includes multihormonal products for the treatment of obesity, including BioChaperone GluExe, which is a combination of glucagon and exenatide; PramExe, which is a combination of pramlintide and exenatide; and BioChaperone PramGluExe, which is a triple combination of pramlintide, glucagon and exenatide. It has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. The company was incorporated in 2005 and is headquartered in Lyon, France.

Metric
Company Name	NETRIS Pharma	Adocia SA
Symbol		ADOC
MSH ID	COM:NETRISPHARMA	COM:ADOCIA
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Pharmaceuticals	Biotechnology
Country	FR	FR
Stage		Post-IPO Debt
Employee Count		78
Website	netrispharma.com	adocia.com
LinkedIn		adocia
Founders

Metric
Market Cap		100.30M
Enterprise Value
Monthly Web Traffic		521
Web Traffic Growth		-0.54
Valuation
Raised Capital		6.96M

Metric
Revenue		2.27M
Revenue (LTM)
Revenue (NTM)
Gross Profit		-18.95M
EBITDA		-18.09M
Operating Income		-18.61M
Net Income		-22.35M
EPS		-2.02
Diluted EPS		-2.02
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		-2.44
Operating Profit Margin		-2.49
EBITDA Margin		-7.96
Net Profit Margin		-2.76
Return on Equity		3.60
Return on Assets		-1.08
Return on Capital Employed		4.03

NETR

COM:NETRISPHARMA

NETRIS Pharma

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-11.60
P/B Ratio		-6.17
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		35.40
EV Multiple		-2.91

Metric
Days Sales Outstanding		275.72
Days Payables Outstanding		745.68
Days Inventory Outstanding		9.81
Operating Cycle		823.59
Cash Conversion Cycle		776.31
Asset Turnover		0.53

Metric
Operating Cash Flow		-5.23M
Free Cash Flow		-5.39M
Cash Flow to Debt		-0.46
Operating Cash Flow/Sales		-1.27
Free Cash Flow Yield		-0.11

Metric
Cash & Equivalents		13.69M
Accounts Receivable		1.23M
Inventory		287.29K
Goodwill
Debt to Capitalization		2.81
Debt to Assets		1.08
Current Ratio		1.05
Quick Ratio		1.01

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue